Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 9/20 | 0.46 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL45796 | 0.88 | MEN1 (0.42) | MAPTMEN1KMT2ALMNAHTT | |
| SCHEMBL1697043 | 0.85 | MEN1 (0.47) | SERPINE1SIRT6MAPTMEN1KMT2A | |
| SCHEMBL45089 | 0.85 | KMT2A (0.46) | MAPTMEN1KMT2ALMNAHTT | |
| SCHEMBL10226318 | 0.83 | MEN1 (0.49) | SIRT6MAPTMEN1KMT2ALMNA | |
| SCHEMBL1696908 | 0.80 | SERPINE1 (0.43) | SERPINE1SIRT6MAPTMEN1KMT2A | |
| SCHEMBL1696339 | 0.80 | MEN1 (0.43) | SERPINE1SIRT6MAPTMEN1KMT2A | |
| SCHEMBL45214 | 0.77 | SERPINE1 (0.47) | SERPINE1SIRT6MAPTMEN1KMT2A | |
| SCHEMBL10225103 | 0.76 | USP30 (0.49) | SERPINE1SIRT6MAPTMEN1KMT2A | |
| SCHEMBL45810 | 0.76 | SERPINE1 (0.46) | SERPINE1SIRT6MAPTMEN1KMT2A | |
| SCHEMBL16691234 | 0.75 | SERPINE1 (0.44) | SERPINE1SIRT6MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150164904-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2015-06-18 | — | — | US | disclosed |
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2014-01-23 | — | — | US | disclosed |
| EP-2591354-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-2590655-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012006473-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012006475-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150164904-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC10A2, SLC34A2, SLC34A1 | SERPINE1 2242/4885SIRT6 3195/4885MAPT 3469/4885 |
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC10A2, SLC34A2, SLC34A3 | SERPINE1 2313/4885SIRT6 3256/4885MAPT 3270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.